Dabomb Protein Biotech Corp

Dabomb Protein Biotech Corp maintains a strong liquidity position, with a current ratio of 2.51 and cash and equivalents of TWD 373.2 million, which exceeds the industry median for liquidity coverage. The company's liquidity_fpt score indicates a low liquidity risk, supported by a free cash flow of TWD 9.04 million and a debt-to-equity ratio of 0.35, which is below the industry median for leverage.

Profitability metrics show mixed performance. The company reported a net income of TWD 6.85 million, but operating income was negative at TWD 0.59 million, indicating operational inefficiencies. Return on equity (ROE) of 0.68% and return on assets (ROA) of 0.49% are below the industry median for both metrics, suggesting underperformance in capital efficiency and asset utilization.

Geographically, Dabomb Protein Biotech Corp's revenue is concentrated in a single market, with no disclosed diversification across regions. This concentration increases exposure to local economic and regulatory shifts, though the company has not disclosed any material geographic risk in its filings.

The company's growth trajectory is modest, with no significant revenue growth reported in the latest period. Outlook data indicates a projected revenue increase of less than 5% in the current fiscal year, with no material changes expected in the next fiscal year. This aligns with the industry's conservative growth expectations for plant-based protein companies.

Risk factors include a low dilution potential, with no recent equity issuance or shelf registration activity detected. The company's shares outstanding remain unchanged at 71.94 million, and no dilution risk is flagged in the risk assessment. However, the negative operating income raises concerns about long-term sustainability without operational improvements.

Recent events include the filing of a 10-K that disclosed no material changes in operations or capital structure. The company has not issued any new products or entered new markets in the past 12 months, and no material earnings call transcripts or regulatory actions have been reported.

Cash conversion ratio of 2.81 ranks in the top quartile, significantly outperforming the cohort median of 0.98.

Debt-to-equity ratio of 0.35 is below the cohort median of 0.32, suggesting a relatively conservative leverage position.

Capex to revenue ratio of -1.2% is above the 75th percentile, implying lower capital intensity than most peers.

Dilution and liquidity risks are assessed as low, providing a stable capital structure environment for investors.

Revenue declined 10% annually over four years, signaling a persistent and significant contraction in top-line growth.

Return on equity of 0.68% is in the bottom quartile, far below the cohort median of 4.99%.

Credit risk is flagged as high, indicating significant potential for financial distress or default issues.